- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03333915
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese Subjects With Advanced Ovarian Cancer, Fallopian Cancer, and Primary Peritoneal Cancer or Advanced Triple Negative Breast Cancer
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230001
- Anhui Provincial Cancer Hospital
-
-
Beijing
-
Beijing, Beijing, China, 100034
- Peking University First Hospital
-
Beijing, Beijing, China, 100142
- Beijing Cancer Hospital
-
Beijing, Beijing, China, 100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
Beijing, Beijing, China, 100032
- Peking Union Medical College Hospital
-
Beijing, Beijing, China, 100034
- Peking University People Hospital
-
-
Changchun
-
Jilin, Changchun, China, 130021
- The First Bethune Hospital of Jilin University
-
-
Chongqing
-
Chongqing, Chongqing, China, 400030
- Chongqing Cancer Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China, 528400
- Sun Yat-sen Memorial Hospital,Sun Yat-sen University
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150000
- Harbin Medical University Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430079
- Hubei Cancer Hospital
-
Wuhan, Hubei, China, 430030
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, China, 410006
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Jiangsu Province Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Jiangxi Maternal and Child Health Hospital
-
-
Jilin
-
Changchun, Jilin, China, 130022
- The Second Hospital of Jilin University
-
Changchun, Jilin, China, 130021
- Jilin cancer hospital
-
-
Liaoning
-
Dalian, Liaoning, China, 116044
- The First Hospital of Dalian Medical University
-
Dalian, Liaoning, China, 215000
- The First Affiliated Hospital of Xian Jiaotong University
-
Shenyang, Liaoning, China, 110042
- Liaoning Cancer Hospital&Institute
-
-
Shandong
-
Jinan, Shandong, China, 250012
- Qilu Hospital of Shandong University
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Fudan University Shanghai Cancer Center
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital Sichuan University
-
-
Tianjin
-
Tianjin, Tianjin, China, 300070
- Tianjin Medical University Cancer Institute & Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Zhejiang Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Participants have voluntarily agreed to participate by giving written informed consent.
- Age 18 years (including 18 years) on the day of signing informed consent.
- Participants meet the following eligibility criteria for the corresponding part of the study: 1) In Phase 1 portion: The participants must have a histologically or cytologically confirmed locally advanced or metastatic cancer, either triple-negative breast cancer or epithelial, non-mucinous, high-grade ovarian cancer (including fallopian cancer, or primary peritoneal cancer), for which no effective standard therapy is available.
2) In Phase 2 portion: Participants who have histologically or cytologically confirmed high-grade epithelial ovarian cancer (including fallopian cancer or primary peritoneal cancer), harboring germline BRCA1/2 mutation 4. Participants must have measurable disease as defined per the RECIST, version 1.1.
5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
Key Exclusion Criteria:
- Participants who have been treated with chemotherapy, biologic therapy, immunotherapy, investigational agent, anti-cancer Chinese medicine, or anticancer herbal remedies ≤ 14 days (or ≤5 half-lives, whichever is shorter) prior to starting study drug, or who have not adequately recovered from the side effects of such therapy.
- Participants who have undergone major surgery for any cause ≤ 4 weeks prior to starting study drug. Participants must have adequately recovered from the previous treatment and have a stable clinical condition before entering the study.
- Participants who have undergone radiotherapy for any cause ≤ 14 days prior to starting study drug. Participants must have adequately recovered from the previous treatment and have a stable clinical condition before entering the study.
- Untreated and/or active brain metastases.
- Prior therapies targeting poly (ADP-ribose) polymerase (PARP).
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1: 20 milligram (mg) pamiparib
20 mg pamiparib twice a day for 21 days
|
Pamiparib is provided as oral capsules
Other Names:
|
Experimental: Phase 1 : 40 mg pamiparib
40 mg pamiparib twice a day for 21 days
|
Pamiparib is provided as oral capsules
Other Names:
|
Experimental: 60 mg pamiparib
60 mg pamiparib twice a day for 21 days
|
Pamiparib is provided as oral capsules
Other Names:
|
Experimental: 60 mg pamiparib in platinum-sensitive ovarian cancer (PSOC)
60 mg pamiparib twice a day until occurrence of unacceptable toxicities, disease progression, withdrawal of consent or investigator discretion
|
Pamiparib is provided as oral capsules
Other Names:
|
Experimental: 60 mg pamiparib in platinum resistant ovarian cancer (PROC)
60 mg pamiparib twice a day until occurrence of unacceptable toxicities, disease progression, withdrawal of consent or investigator discretion
|
Pamiparib is provided as oral capsules
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: Number of Participants With Treatment- Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)
Time Frame: From first dose to within 30 days of last dose of pamiparib (approximately 36 months)
|
A TEAE is defined as an adverse event (AE) that had an onset date on or after the first dose of study drug up to 30 days following study drug discontinuation or was worsening in severity from baseline (pretreatment).
|
From first dose to within 30 days of last dose of pamiparib (approximately 36 months)
|
Phase 1: Number of Participants With Clinically Significant Abnormalities in Physical Examinations and Electrocardiograms (ECGs)
Time Frame: From first dose to within 30 days of last dose of pamiparib (approximately 36 months)
|
From first dose to within 30 days of last dose of pamiparib (approximately 36 months)
|
|
Phase 2: Objective Response Rate (ORR) in High Grade Ovarian Cancer (HGOC) Both PSOC and PROC as Assessed by Independent Radiology Review Committee (IRC)
Time Frame: Up to approximately 2 years and 8 months
|
ORR is defined as the percentage of participants with confirmed Complete Response or Partial Response
|
Up to approximately 2 years and 8 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: Maximum Observed Plasma Concentration (Cmax)
Time Frame: Cycle 1 Day 1 and Day 10 of 21-day cycle: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
Cycle 1 Day 1 and Day 10 of 21-day cycle: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
|
Phase I: Time to Reach Cmax (Tmax)
Time Frame: Cycle 1 Day 1 and Day 10 of 21-day cycle: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
Cycle 1 Day 1 and Day 10 of 21-day cycle: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
|
Phase I: Terminal Elimination Half-life (t1/2)
Time Frame: Cycle 1 Day 1 of 21-day cycle: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
Cycle 1 Day 1 of 21-day cycle: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
|
Phase I: Apparent Clearance (CL/F)
Time Frame: Cycle 1 Day 1 of 21-day cycle: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
Cycle 1 Day 1 of 21-day cycle: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
|
Phase 1: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUCinf)
Time Frame: Cycle 1 Day 1 of 21-day cycle: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
Cycle 1 Day 1 of 21-day cycle: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
|
Phase I: Apparent Volume of Distribution During Terminal Phase (Vz/F)
Time Frame: Cycle 1 Day 1 of 21-day cycle: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
Cycle 1 Day 1 of 21-day cycle: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
|
Phase I: Confirmed Objective Response Rate (ORR) as Assessed by the Investigator Per RECIST v1.1
Time Frame: Up to approximately 36 months
|
ORR is defined as the percentage of participants with confirmed Complete Response (CR) or Partial Response (PR)
|
Up to approximately 36 months
|
Phase 1: Disease Control Rate (DCR) Assessed by the Investigator Per RECIST v1.1
Time Frame: Up to approximately 36 months
|
DCR is defined as the percentage of participants with best overall response (BOR) of CR, PR and stable disease (SD)
|
Up to approximately 36 months
|
Phase I: Clinical Benefit Rate (CBR) Assessed by the Investigator Per RECIST v1.1
Time Frame: Up to approximately 36 months
|
CBR is defined as percentage of participants with best overall response of CR, PR and stable disease (SD)≥24 weeks
|
Up to approximately 36 months
|
Phase 1: Duration of Response (DOR) as Assessed by Investigator Per RECIST v1.1
Time Frame: Up to approximately 36 months
|
DOR is defined as the time from the first determination of a confirmed overall response until the first documentation of progression or death, whichever comes first
|
Up to approximately 36 months
|
Phase I : Progression Free Survival (PFS)
Time Frame: Up to approximately 36 months
|
PFS is defined as the time from first dose of study medication to the first documented disease progression or death due to any cause, whichever occurs first
|
Up to approximately 36 months
|
Phase 2: Objective Response Rate (ORR) by Investigator Per RECIST v1.1
Time Frame: Up to approximately 3 years and 8 months
|
ORR is defined as the percentage of participants with confirmed Complete Response or Partial Response
|
Up to approximately 3 years and 8 months
|
Phase 2: Disease Control Rate by Investigator Per RECIST v1.1
Time Frame: Up to approximately 3 years and 8 months
|
DCR is defined as the percentage of participants with best overall response (BOR) of CR, PR and stable disease (SD)
|
Up to approximately 3 years and 8 months
|
Phase 2: Clinical Benefit Rate by Investigator Per RECIST v1.1
Time Frame: Up to approximately 3 years and 8 months
|
CBR is defined as percentage of participants with best overall response of CR, PR and stable disease (SD)≥24 weeks
|
Up to approximately 3 years and 8 months
|
Phase 2: Carcinoma Antigen-125 (C(A-125) Response Rate by Gynecologic Cancer Inter Group (GCIG )Criteria
Time Frame: Up to approximately 3 years and 8 months
|
CA-125 response is defined the percentage of participants with at least 50% reduction in CA-125 levels from pre-treatment sample
|
Up to approximately 3 years and 8 months
|
Phase 2: Duration of Response as Assessed by Investigator Per RECIST v1.1
Time Frame: Up to approximately 3 years and 8 months
|
DOR is defined as the time from the first determination of a confirmed overall response until the first documentation of progression or death, whichever comes first
|
Up to approximately 3 years and 8 months
|
Phase 2: Progression Free Survival as Assessed by the Investigator Per RECIST v1.1
Time Frame: Up to approximately 3 years and 8 months
|
PFS is defined as the time from first dose of study medication to the first documented disease progression or death due to any cause, whichever occurs first
|
Up to approximately 3 years and 8 months
|
Phase 2: Overall Survival (OS) as Assessed by Investigator
Time Frame: Up to approximately 3 years and 8 months
|
OS is defined as time from the first dose of study medication to the date of death due to any cause
|
Up to approximately 3 years and 8 months
|
Phase 2: Number of Participants With Treatment- Emergent Adverse Events and Serious Adverse Events
Time Frame: From first dose to within 30 days of last dose of pamiparib (approximately 3 years and 8 months)
|
A TEAE is defined as an adverse event (AE) that had an onset date on or after the first dose of study drug up to 30 days following study drug discontinuation or was worsening in severity from baseline (pretreatment).
All clinically significant abnormalities in physical examinations, laboratory tests and ECGs are reported as adverse events (AE) in the AE section.
|
From first dose to within 30 days of last dose of pamiparib (approximately 3 years and 8 months)
|
Phase 2: Area Under the Plasma Concentration-time Curve From 0 to 12 Hours Post-dose (AUC0-12)
Time Frame: Cycle 1 Day 1 and Cycle 2 Day 1: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
Cycle 1 Day 1 and Cycle 2 Day 1: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
|
Phase 2: Maximum Observed Plasma Concentration (Cmax)
Time Frame: Cycle 1 Day 1 and Cycle 2 Day 1: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
Cycle 1 Day 1 and Cycle 2 Day 1: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
|
Phase 2: Time to Reach Cmax (Tmax)
Time Frame: Cycle 1 Day 1 and Cycle 2 Day 1: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
Cycle 1 Day 1 and Cycle 2 Day 1: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
|
Phase 2: Area Under the Plasma Concentration-time Curve From 0 to the 9 Hours Post-dose (AUC0-9)
Time Frame: Cycle 1 Day 1 and Cycle 2 Day 1: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
Cycle 1 Day 1 and Cycle 2 Day 1: pre-dose, 0.5, 1, 2, 4, 6,9 and 12 hours post dose
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Study Director, BeiGene
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Breast Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Breast Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Triple Negative Breast Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Pamiparib
Other Study ID Numbers
- BGB-290-102
- CTR20160828 (Registry Identifier: ChiCTR)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Triple Negative Breast Cancer
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Swiss Group for Clinical Cancer ResearchNot yet recruitingTriple-negative Breast Cancer | TNBC - Triple-Negative Breast CancerSwitzerland
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); MedImmune...TerminatedTriple Negative Breast Cancer | Triple Negative Breast Neoplasms | TNBC - Triple-Negative Breast Cancer | Triple-negative Breast CarcinomaUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
AkesoRecruitingMetastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast CancerChina
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
Fudan UniversityNot yet recruitingTriple-negative Breast Cancer
-
Fudan UniversityRecruitingTriple-Negative Breast CancerChina
-
Fudan UniversityRecruiting
-
Fudan UniversityRecruiting
Clinical Trials on Pamiparib
-
Peter MacCallum Cancer Centre, AustraliaRecruiting
-
BeiGeneCompletedAdvanced Solid TumorsUnited Kingdom
-
Fudan UniversityRecruitingLimited Stage Small Cell Lung CancerChina
-
BeiGeneTerminatedMetastatic Castration-Resistant Prostate Cancer (mCRPC) | Homologous Recombination Deficiency (HRD)United States, Australia, Puerto Rico, Spain
-
Australia New Zealand Gynaecological Oncology GroupBeiGeneWithdrawn
-
Bai-Rong XiaRecruiting
-
BeiGeneCompletedHER2-negative Breast CancerChina
-
Sun Yat-sen UniversityRecruitingMetastatic Castration-resistant Prostate CancerChina
-
BeiGeneActive, not recruiting
-
BeiGene USA, Inc.CompletedBrain and Central Nervous System TumorsUnited States, Netherlands, Switzerland